In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Companies Look West, East, Anyplace But US

Executive Summary

With clear regulatory approval paths in Europe and growing markets in Asia and other developing markets, device executives and investors see international markets as increasingly attractive alternatives for clinical validation, revenue, and regulatory approval.

You may also be interested in...



Huge Markets For Devices Emerging In Brazil, Latin America

Nearly stalled Western economies have driven corporations of all stripes to ponder the market potential promised by the so-called BRIC countries (Brazil, Russia, India and China). The medical device industry is no exception. The BRIC nations present a challenging but lucrative opportunity for companies willing to deviate from traditional markets to access economies with GDPs that place them in the top 15 economies in the world. Of the BRIC nations, China has become the number one destination for health care technology companies in the minds of CEOs of commercial-stage medical device companies. But executives staring only on China might be missing another compelling opportunity that literally rests under their noses: Latin America.

TriReme Strategy Bridges Pacific For Medical Device Start-Ups

The road to the rising markets of Asia can be daunting to some medical device start-ups, but not Pleasanton, CA-based TriReme Medical Inc. For the past two years, the privately held maker of balloon-equipped catheters has constructed inroads to Asia through the city-state of Singapore. Two years ago, the company established a subsidiary in Singapore, enabling it to dip into the Asia-based capital pool.

Covidien Still Hungry For GI After Barrx Buy

Just as it did with VNUS, Covidien snapped up a smaller leader in a field where it had very little contact – esophageal cancer and its precursor Barrett’s esophagus – with the intent of building a larger presence. Covidien paid $325 million for Barrx Medical Inc., developer of a radiofrequency tool capable of eliminating Barrett’s, a condition in which damaged esophageal tissue presents an elevated risk of developing into esophageal cancer.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

WI964842

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel